Back to Search
Start Over
Type 1 diabetes mellitus with diabetic ketoacidosis after immune checkpoint inhibitor therapy
- Source :
- Journal of Cancer Research and Practice, Vol 5, Iss 4, Pp 153-155 (2018)
- Publication Year :
- 2018
- Publisher :
- Wolters Kluwer Medknow Publications, 2018.
-
Abstract
- Treatment with immune checkpoint inhibitors (ICIs) has introduced a new era of cancer therapy. Although ICIs are not closely associated with the side effects associated with chemotherapy such as nausea, vomiting and cytopenia, there are still adverse effects which are related to the blockade of normal immune regulatory mechanisms. Herein, we report a patient with adenocarcinoma of the gastroesophageal junction with liver metastasis who developed diabetic ketoacidosis after ICI therapy even though he had no history of diabetes mellitus (DM). The acute onset of DM can occur in patients who receive ICI therapy. The possibility of developing such a hyperglycemic side effect should be kept in mind. Keywords: Immune checkpoint inhibitor, Immune-related adverse effect, Type 1 diabetes mellitus
- Subjects :
- Cultural Studies
Oncology
Linguistics and Language
History
medicine.medical_specialty
Side effect
Diabetic ketoacidosis
Nausea
medicine.medical_treatment
030209 endocrinology & metabolism
lcsh:RC254-282
Language and Linguistics
03 medical and health sciences
0302 clinical medicine
Internal medicine
Diabetes mellitus
medicine
Adverse effect
Cytopenia
Type 1 diabetes
Chemotherapy
business.industry
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
030220 oncology & carcinogenesis
Anthropology
medicine.symptom
business
Subjects
Details
- Language :
- English
- ISSN :
- 23113006
- Volume :
- 5
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Journal of Cancer Research and Practice
- Accession number :
- edsair.doi.dedup.....4fe424ebb351302aeebb89782defd6b7